Tirzepatide has improved kidney function and cardiovascular effects between patients with obesity and heart failure with a preserved extrusion fraction (HFPEF) compared to placebo in one year, according to the displayed clinical surveys. Jacc. The overall rate of cardiovascular death or the deterioration of heart failure, the main end point of the test, was higher in 60% of study participants who also had chronic kidney disease. However, Tizepatide reduced the risk of primary end point to a similar degree to patients with and without kidney disease.
In the new analysis of the data from the summit, the researchers focused on patients with obesity, chronic kidney disease and HFPEF because they usually have interactive radical causes and are associated with poor outcomes, indicating a significant unfulfilled need.
The interaction of these three conditions identifies a population of patients as extremely high risk, which means that it is a population of patients who are extremely in need of functioning treatments. This drug improves kidney function, obesity and HFPEF results, thereby improving the three elements that interact to create this syndrome. “
Milton Packer, MD, distinguished scholar in cardiovascular science at Baylor University Medical Center in Dallas and the first author of the study
The HFPEF occurs when the heart muscle cannot be sufficiently expanded to accommodate the blood it receives, causing pressure on the heart to rise. Chronic kidney disease occurs when the kidneys do not filter out blood waste properly, leading to the accumulation of toxins. Both are chronic diseases that are progressively deteriorating over time.
Tipaepatide aims at two receptors to shrink fat cells and reduce the effects of enlarged adipose cells on heart and kidney health. The drug is approved by the US Food and Drug Administration for the treatment of obesity through its effects on weight loss, as well as for the treatment of type 2 diabetes through its effect on blood sugar levels. Previous studies have shown improved kidney function with other medicines in the same class, but this test is the first to evaluate the impact of Tizpapatide on kidney and cardiovascular effects on people with obesity, chronic kidney disease and HFPEF, a three -year -old US.
Top test participated 731 patients with HFPEF and body mass index of 30 m2/kg or higher. About 60% of study participants also had chronic kidney disease. Half were randomly commissioned to receive tirzepatide and half received placebo. Neither the patients nor the clinical doctors knew what they had been assigned.
In one year, patients who received Tizepatide had a 38% lower percentage of cardiovascular death or deterioration of heart failure (defined as deterioration of symptoms of heart failure in addition to hospitalization or intensification of diuretic drugs). Participants who received Tirzepatide also had a better average of Kansas City’s cardiomyopathy from the placebo group, from the placebo group, showing a significant improvement in the second primary end point of the study, a measure of severity of heart failure.
For both of these primary endpoints, the researchers watched a similar improvement with Tizepatide in patients with and without chronic kidney disease. Overall, participants with chronic kidney disease treated the poorer results in multiple measurements compared to participants without chronic kidney disease, facing more severe symptoms of heart failure on average and seeing twice the risk of deterioration of heart failure.
The researchers used two strategies to evaluate kidney function, meatinine and cystatin C measurement at 12, 24 and 52 weeks. Eventually, participants who received Tirzepatide showed significant improvements compared to those who took placebo in terms of both renal function indicators, although the results showed different standards over time and between different groups of patients.
“Most patients with obesity who have HFPEF and chronic kidney disease do not get any effective treatment,” Packer said. “We were very happy to see the improvement of kidney function, which was paralleled with the favorable effects on the heart and obesity.”
Researchers said that both creatinine and cystatin C levels can be affected by factors such as obesity and skeletal muscle mass. Despite the possible merger, the agreement between the two measurements on the direction of change between study groups offers a confirmation of Tipaepatide’s positive effect on kidney function, Packer said.
Researchers are planning to continue analyzing data from the top test for further ideas on molecular mechanisms that contribute to the interaction between obesity, kidney disease and heart failure.
The study was funded by Eli Lilly and the company.
This study was published simultaneously on the internet at Jacc at the time of the presentation.
Source:
Magazine report:
Packer, M., et al. (2025) The interaction of chronic kidney disease and the effects of Tizpatide on patients with heart failure, preserved extrusion fraction and obesity: Top test. Jacc. doi.org/10.1016/j.jacc.2025.03.009.
